200 related articles for article (PubMed ID: 37836790)
1. Discovery of a SHP2 Degrader with In Vivo Anti-Tumor Activity.
Miao J; Bai Y; Miao Y; Qu Z; Dong J; Zhang RY; Aggarwal D; Jassim BA; Nguyen Q; Zhang ZY
Molecules; 2023 Oct; 28(19):. PubMed ID: 37836790
[TBL] [Abstract][Full Text] [Related]
2. Proteolysis-targeting chimera molecules targeting SHP2.
Yu D; Zheng M; Liu Y; Chen L; Li H
Future Med Chem; 2022 Apr; 14(8):587-600. PubMed ID: 35297283
[TBL] [Abstract][Full Text] [Related]
3. Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders.
Yang X; Wang Z; Pei Y; Song N; Xu L; Feng B; Wang H; Luo X; Hu X; Qiu X; Feng H; Yang Y; Zhou Y; Li J; Zhou B
Eur J Med Chem; 2021 Jun; 218():113341. PubMed ID: 33780898
[TBL] [Abstract][Full Text] [Related]
4. Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein.
Wang M; Lu J; Wang M; Yang CY; Wang S
J Med Chem; 2020 Jul; 63(14):7510-7528. PubMed ID: 32437146
[TBL] [Abstract][Full Text] [Related]
5. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
[TBL] [Abstract][Full Text] [Related]
6. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
Ishida T; Ciulli A
SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
[TBL] [Abstract][Full Text] [Related]
7. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
[TBL] [Abstract][Full Text] [Related]
8. Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders.
Tang K; Jia YN; Yu B; Liu HM
Eur J Med Chem; 2020 Oct; 204():112657. PubMed ID: 32738411
[TBL] [Abstract][Full Text] [Related]
9. Modulation of fatty acid synthase degradation by concerted action of p38 MAP kinase, E3 ligase COP1, and SH2-tyrosine phosphatase Shp2.
Yu J; Deng R; Zhu HH; Zhang SS; Zhu C; Montminy M; Davis R; Feng GS
J Biol Chem; 2013 Feb; 288(6):3823-30. PubMed ID: 23269672
[TBL] [Abstract][Full Text] [Related]
10. Targeted Degradation of the Oncogenic Phosphatase SHP2.
Vemulapalli V; Donovan KA; Seegar TCM; Rogers JM; Bae M; Lumpkin RJ; Cao R; Henke MT; Ray SS; Fischer ES; Cuny GD; Blacklow SC
Biochemistry; 2021 Aug; 60(34):2593-2609. PubMed ID: 34411482
[TBL] [Abstract][Full Text] [Related]
11. Development of decoy oligonucleotide-warheaded chimeric molecules targeting STAT3.
Shih PC; Naganuma M; Tsuji G; Demizu Y; Naito M
Bioorg Med Chem; 2023 Nov; 95():117507. PubMed ID: 37922656
[TBL] [Abstract][Full Text] [Related]
12. Targeting endogenous proteins for degradation through the affinity-directed protein missile system.
Fulcher LJ; Hutchinson LD; Macartney TJ; Turnbull C; Sapkota GP
Open Biol; 2017 May; 7(5):. PubMed ID: 28490657
[TBL] [Abstract][Full Text] [Related]
13. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
14. Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression.
Wang K; Dai X; Yu A; Feng C; Liu K; Huang L
J Exp Clin Cancer Res; 2022 Sep; 41(1):289. PubMed ID: 36171633
[TBL] [Abstract][Full Text] [Related]
15. Recent advancements in the discovery of cereblon-based protease-targeted chimeras with potential for therapeutic intervention.
Singh H; Agrawal DK
Future Med Chem; 2022 Oct; 14(19):1403-1416. PubMed ID: 36047364
[TBL] [Abstract][Full Text] [Related]
16. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
[TBL] [Abstract][Full Text] [Related]
17. SHP2 promotes proliferation of breast cancer cells through regulating Cyclin D1 stability
Yuan Y; Fan Y; Gao Z; Sun X; Zhang H; Wang Z; Cui Y; Song W; Wang Z; Zhang F; Niu R
Cancer Biol Med; 2020 Aug; 17(3):707-725. PubMed ID: 32944401
[No Abstract] [Full Text] [Related]
18. Novel PROTACs for degradation of SHP2 protein.
Zheng M; Liu Y; Wu C; Yang K; Wang Q; Zhou Y; Chen L; Li H
Bioorg Chem; 2021 May; 110():104788. PubMed ID: 33706076
[TBL] [Abstract][Full Text] [Related]
19. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.
Maniaci C; Hughes SJ; Testa A; Chen W; Lamont DJ; Rocha S; Alessi DR; Romeo R; Ciulli A
Nat Commun; 2017 Oct; 8(1):830. PubMed ID: 29018234
[TBL] [Abstract][Full Text] [Related]
20. Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.
Li R; Liu M; Yang Z; Li J; Gao Y; Tan R
Molecules; 2022 Dec; 27(24):. PubMed ID: 36557960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]